Roche CEO Urges Antitrust Regulators to Block Novo Holdings’ Acquisition of Catalent

Roche's Opposition:
Roche CEO Thomas Schinecker has expressed opposition to Novo Holdings' proposed $16.5 billion acquisition of contract manufacturer Catalent, citing potential negative impacts on industry competition.

Industry Concerns:
The deal could further restrict the contract manufacturing ecosystem, potentially harming smaller players in the industry.

Regulatory Pressure:
Consumer groups, labor unions, and Sen. Elizabeth Warren have also urged the Federal Trade Commission to block the acquisition due to anti-competitive concerns.

Eli Lilly's Concerns:
Eli Lilly CEO David Ricks has expressed similar concerns, noting that the company relies on Catalent for GLP-1 and other diabetes production.

Potential Market Impact:
The acquisition could give Novo Nordisk significant control over the GLP-1 market, potentially increasing prices and reducing competition.